Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
Read Article
Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
https://t.co/WmON0xyaKa https://t.co/UVbcJv5o1p
Dr. John Cush @RheumNow( View Tweet )
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/4JfUueF55o https://t.co/hBkgYU1Mye
Dr. John Cush @RheumNow( View Tweet )
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.
https://t.co/PRjy4a1BG9 https://t.co/3J4NSmn6Su
Dr. John Cush @RheumNow( View Tweet )
Diagnoses via Immune ‘Fingerprints’
Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct
Read Article
ACPA+ linked to nodule progression. 208 #RA pts w/ Chest CT studied. Lung nodules seen in 1/3; 10% before RA Dx (10.4 mos before). Positive ACPA (not RF) was assoc w/ nodule progression (OR 3.69). csDMARDs & b/ts-DMARDs NO affect on nodule progression. https://t.co/GO1wLRIl9j https://t.co/pfFGbPv2DG
Dr. John Cush @RheumNow( View Tweet )
US nationwide claims data study of CV outcomes (MACE) in #RA based on b/tsDMARD (n=34375) exposures (71% TNFi, 10% JAKi, 8% ABA, 5% RTX, 5% IL-6i). Compared to TNFi, RTX (HR 1.5) & IL-6i (HR 1.3) had numerically higher, but not statistically significant, MACE risk.… https://t.co/GXunfMY3US https://t.co/XYZPt0kzGE
Dr. John Cush @RheumNow( View Tweet )
Srudy of 558 #RA pts finds GERD symptoms were significantly w/ higher TJC28 and VAS scores and lower use of MTX (but not related to NSAID or steroid use). GERD Sxs may impact MTX dosing and Dz activity measures in RA https://t.co/2H8RUNywlG https://t.co/ZBSlTL1ZA3
Dr. John Cush @RheumNow( View Tweet )
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/29CG4bwlYR
Dr. John Cush @RheumNow( View Tweet )
CRP and Hidradenitis Supprativa
A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.… https://t.co/VxFRjt3cRw https://t.co/rdNIvzMaP8
Dr. John Cush @RheumNow( View Tweet )
Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025
Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA
FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/9er7TkNXpK https://t.co/N6sal9URv3
Links:
Dr. John Cush @RheumNow( View Tweet )
Risk for Serious Infection with Low-Dose Glucocorticoids in RA
https://t.co/5frAX3W7Hz https://t.co/PHeqCacxKa
Dr. John Cush @RheumNow( View Tweet )
A common clinical phenotype arising from diverse pathogenic mechanisms. Study of PBMC transcriptomes (ACPA+ at-risk vs early ACPA+ RA vs controls). A TF signature was enriched in early RA & at-risk individuals (involving SUMOylation, RUNX2, YAP1, NOTCH3, β-Catenin). Cells w/… https://t.co/vCDEjIMXWa https://t.co/mizo7AXWvr
Dr. John Cush @RheumNow( View Tweet )
Australian population study of 14,041 RA pts (68% F; age 65 yrs) vs 33,785 controls, preexisting cancer (CA) in RA was less prevalent (7.6% vs 14.2%). Cancer incid. rates lower in RA (CIR 19.68 vs 24.77) & stable over 3 decades. RA CIR higher for lung (CIR 1.17) & heme CA (CIR… https://t.co/k5KRwYT6jl https://t.co/MVfmuTGlth
Dr. John Cush @RheumNow( View Tweet )
Three B-cell targeting anti-CD20 mAbs in clinical use:
- Rituximab (1997) for RA, GPA, CLL, NHL, Pemphigus Vulgaris
- Ofatumumab (2020) for relapsing MS
- Obinutuzumab (2013) for Follicular lymphoma & CLL
OFA & OBIN may be better than RTX in membranous GN pts w/ anti-RTX Abs… https://t.co/ZhUbXFXjSR https://t.co/vUHkS76PK7
Dr. John Cush @RheumNow( View Tweet )
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
https://t.co/ZsS3JOqdLh https://t.co/3JByNrLTGR
Links:
Dr. John Cush @RheumNow( View Tweet )
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/KpdY1MEM1w https://t.co/vETGMJgHf3
Dr. John Cush @RheumNow( View Tweet )
Korean insurance claims data shows #RA pts have a higher risk of renal cancer (vs gen. population), unrelated to serostatus. The renal CA risk (aHR 1.34;1.04–1.78) was higher in women (aHR 1.57); but RA was not assoc w/ risk of CA of bladder, prostate or testes… https://t.co/owSeqibcPu https://t.co/N3TRQuKZJs
Dr. John Cush @RheumNow( View Tweet )
Japanese study of 781 RA pts (78 dx w/ ILD; most UIP pattern). Mortality higher in RA-ILD (SMR 2.09) vs RA (1.16) vs gen population. Mortality increased w/ ILD (adj HR 2.97), advanced age (1.08/per yr) , and low BMI (3.07) https://t.co/EYKfHotZPr https://t.co/xC6E0OLfFs
Dr. John Cush @RheumNow( View Tweet )
Combination biologics in PsA: are we there yet?
Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush @RheumNow( View Tweet )
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
The manufacturer, Anaptys, issued a press release regarding rosnilimab, a drug being developed for use in
Read Article
That's not my problem - or is it? Multimorbidity in RA
RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment.
https://t.co/4lSVKeRtyx https://t.co/Xa1UGbJigy
Dr. John Cush @RheumNow( View Tweet )
Full read review of association betw #RA & Chikungunya fever (viral infxn transmitted by Aedes mosquitoes). Theres no true link betw RA & CHIKV; but incidence of RA after CHIKV is 13.7% (based on 16 reports, 2879 pts, 449 RA postCHIKV) https://t.co/8fxIS846Nd https://t.co/YD1aLIVrrI
Dr. John Cush @RheumNow( View Tweet )
8 fold risk of incident ILD in #RA pts. Data from Korean National Health Insurance, 52,325 RA pts & 261,625 controls & 4.4 yrs F/U - ILD in 3.7% of RA vs 0.5% controls (adjHR 7.84); higher in seropositive RA (aHR= 9) vs seronegative RA (aHR=4.8) https://t.co/iIoZOwFYEN https://t.co/HBzSg9KrpZ
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
